ALPMY News and Press, Astellas Pharma Inc. ADR From 02/04/22

Astellas Pharma (OTCPK:ALPMY): 9M Non-GAAP core basic EPS of ¥91.57, compared to ¥89.71 in the first nine months of FY2020. Revenue of ¥992.29B (+5.5% Y/Y). Outlook: For further details see: Astellas Pharma reports 9M results

Astellas and Seagen Receive Positive CHMP Opinion for PADCEV™ (enfortumab vedotin) in Locally Advanced or Metastatic Urothelial Cancer - If approved, PADCEV would be the first medicine for patients in the EU who have received prior platinum-based chemotherapy and a PD-1/L...

Astellas and MBC BioLabs Announce Future Innovator Prize Winners - Helping Biotech Start-ups Accelerate Early Research Efforts - Vcreate and Weatherwax Biotechnologies win a year of access to life-science incubator in San Francisco, CA and to Astellas expertise to further their ...

Astellas and Dyno Therapeutics Announce Research Collaboration to Develop Next-Generation AAV Gene Therapy Vectors for Skeletal and Cardiac Muscle - Dyno receives $18 million upfront and is eligible for milestone and royalty payments potentially exceeding $1.6 billion - PR N...

Astellas to Present Research on FLT3 Mutation-Positive Acute Myeloid Leukemia - from Diagnosis to Relapse - at 2021 American Society of Hematology Annual Meeting - Four AML oral presentations are among highest number of Astellas-sponsored ASH abstracts to date - Full results...

Relugolix is approved and launched in two indications and could establish itself as a new Standard of Care. The inked 4.2 billion deal with top-class partner Pfizer verifies the blockbuster potential of Relugolix. Quarterly reports reflect initial sales success and combined with s...

Tweedy, Browne Company LLC provides investment advisory services. The Company offers portfolio management, financial planning, and consulting services for individuals, institutions, partnerships, pension and profit-sharing plans, charitable foundations, trusts, and offshore funds. Tweedy,...

Astellas and LabCentral Announce Future Innovator Prize Winners - Helping Emerging Biotechs Accelerate Growth of Innovative Science - Thymmune Therapeutics and M13 Therapeutics win a year of access to life-science incubator in Cambridge, MA and access to Astellas expertise to fu...

Astellas and Seagen Complete Enrollment in EV-103 Trial Cohort K Combining PADCEV® (enfortumab vedotin-ejfv) with Pembrolizumab as First-Line Treatment for Advanced Urothelial Cancer PR Newswire TOKYO and BOTHELL, Wash. , Oct. 12, 2021 /PRNewswire/ -- As...

Most companies in the pharmaceutical space have been the subject of immense investor attention since the onset of the COVID-19 pandemic last year. The demand for their products and services is expected to increase in the coming months due to an aging population and increasing demand for thera...